Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

BACKGROUND: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines. METHODS: In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no),...

Descripción completa

Detalles Bibliográficos
Autores principales: Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056058/
https://www.ncbi.nlm.nih.gov/pubmed/24823696
http://dx.doi.org/10.1038/bjc.2014.244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056058/
https://www.ncbi.nlm.nih.gov/pubmed/24823696
http://dx.doi.org/10.1038/bjc.2014.244

Ejemplares similares